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ABSTRACT 
Radiotherapy plays a vital role in cancer treatment, for which accurate 
prognosis is important for guiding sequential treatment and improving the 
curative effect for patients. An issue of great significance in radiotherapy 
is to assess tumor radiosensitivity for devising the optimal treatment 
strategy. Previous studies focused on gene expression in cells closely 
associated with radiosensitivity, but factors such as the response of a cancer 
patient to irradiation and the patient survival time are largely ignored. For 
clinical cancer treatment, a specific pre-treatment indicator taking into 
account cancer cell type and patient radiosensitivity is of great value but it 
has been missing. Here, we propose an effective indicator for 
radiosensitivity: radiosensitive gene group centrality (RSGGC), which 
characterizes the importance of the group of genes that are radiosensitive 
in the whole gene correlation network. We demonstrate, using both clinical 
patient data and experimental cancer cell lines, which RSGGC can provide 
a quantitative estimate of the effect of radiotherapy, with factors such as 
the patient survival time and the survived fraction of cancer cell lines under 
radiotherapy fully taken into account. Our main finding is that, for patients 
with a higher RSGGC score before radiotherapy, cancer treatment tends to 
  
be more effective. The RSGGC can have significant applications in clinical 
prognosis, serving as a key measure to classifying radiosensitive and 
radioresistant patients.    
  
MAIN TEXT 
Introduction 
Radiotherapy has been an indispensable tool for treating cancer and 
controlling its growth, which is received by nearly 50% of the cancer 
patients[1]. A fundamental issue in radiotherapy is to assess the 
radiosensitivity (RS) of a cancer patient to enable decision making toward 
optimal treatment strategy[2]. In the modern era of precise medicine, gene 
signatures as a response predictor for radiotherapy and chemotherapy have 
been effective in the treatment of various cancers[3-6]. Previous studies 
established that a group of 31 genes from NCI-60 cancer cells are closely 
associated with radiotherapy[7]. However, due to the high complexity of 
the gene regulatory system, the intrinsic relationship between these genes 
has been unclear and it remains difficult to predict the effectiveness of 
radiotherapy for cancer patients. 
Network science has the potential to provide powerful tools for 
analyzing a variety of natural and artificial complex systems[8-11], 
including those in life science and medicine. For example, metabolic 
pathways can be identified through analyzing the network structure of 
genes/proteins[12, 13], epidemic outbreak can be explained based on 
  
spreading dynamics on networks[14, 15], ecological stability associated 
with environment can be assessed using the network approach[16], 
designing genetic circuits can benefit from the principles from network 
science[17], and tipping points in complex mutualistic networks can be 
analyzed and predicted[18]. Recently, network science has been employed 
to advance research in cancer and oncology, providing unprecedented 
insights into physiological phenomena related to tumor growth[19, 20]with 
clinical applications[21, 22], clarifying the biochemical factors and 
signaling pathways during primary tumor development[23, 24], and 
leading to pathway-directed drug discovery[25]. The purpose of this paper 
is to exploit principles of complex network science to propose, analyze, 
and validate a geometric indicator to effectively and quantitatively 
characterize the impact of radiotherapy on cancer patients. This is the 
radiosensitive gene group centrality (RSGGC), which can be calculated 
through identifying both the relations among gene signatures and the 
efficiency of the radiotherapy treatment. 
Our work is motivated by the considerations that, in spite of the 
completeness of the Human Genome Project[26], the detailed functions 
  
and relationship among the genes remain unclear, and the existing protein-
protein interaction (PPI) networks are unable to capture the overall features 
of the regulation process. It is thus useful to concentrate on the intrinsic 
properties of the genes with a network dynamic topology. In particular, we 
consider the intergenic correlations among data samples of the same cluster 
or classification to obtain a network through Pearson's correlation matrix, 
which is also known as the gene co-expression matrix[27]. The matrix 
quantifies the gene-gene relationship across tissue samples. In network 
science, the centrality of a node quantifies its importance in the network 
based on the local connection strength to its neighbors[28-30]. Similarly, 
the centrality of a cluster of nodes is the sum of the centrality values over 
all the nodes in the cluster, which characterizes the importance of the focal 
cluster[31]. Based on this concept, we propose RSGGC as a novel indicator 
to quantitatively assess malignant tumor development and to provide 
prognosis for patients. Combining with the finding of work[7], we group 
the 31 radiosensitive genes to be our focal cluster to calculate the RSGGC, 
as shown schematically in Fig. 1. 
Through analysis based on different data sets from patients and cancer 
  
cell lines, we find a strong correlation between RSGGC and the patient's 
clinical or physiological indicators, suggesting that RSGGC can be 
potentially be applied to analyzing the therapeutic effect of radiotherapy. 
Specifically, for clinical data, we collect the previously public datasets 
from Gene Expression Omnibus (GEO) and the Cancer Genome Atlas 
(TCGA) to calculate the correlation between the survival time of a patient 
and his/her RSGGC value from the clinical perspective. We then analyze 
the the experimental data of cancer cell lines from the existing 
literature[32]. A typical data set includes the survival fraction (SF) of 
parallel cell lines with different radiation dosages (2Gy, 5Gy, 8Gy) as labels 
of irradiation resistance for follow-up process. We calculate the RSGGC 
values for the corresponding NCI mRNA expression data. A statistical 
analysis shows that patients with a high RSGGC score have a longer 
survival time after radiotherapy and, consistently, cell lines with a higher 
RSGGC value have a smaller survival fraction after irradiation. Further, for 
different glioblastoma multiforme (GBM) cancer subtypes, our results 
indicate that the higher the RSGGC score is, the better therapeutic effect 
would be for patients receiving radiotherapy. Finally, based on the time 
  
sequencing data associated with irradiation, we compare the values of 
RSGGC before and after irradiation and find a sensitive response of 
RSGGC to irradiation, indicating the potential advantage of using RSGGC 
to assess the effect of radiotherapy in a quantitative manner. Our detailed 
and systematic analysis of RSGGC suggest that it can be used as a potential 
indicator of the effectiveness of radiotherapy to greatly facilitate decision 
making toward an optimal strategy for treating cancer.  
  
Material and Methods 
Data collection 
The required mRNA/cDNA expression profile of a patient or a cancer 
cell line involved in radiotherapy or in irradiation experiment, respectively, 
is collected from the previous published datasets from Gene Expression 
Omnibus (GEO) and the Cancer Genome Atlas (TCGA), with detailed 
information listed in Table I.  
Radiotherapy is the leading therapeutic strategy for patients suffering 
from GBM, as the surgical risk for this type of cancer is greater than others. 
GBM thus provides substantially more radiotherapy cases in the test 
datasets (GSE7696[33], GSE16011[34], and TCGA-GBM). In order to 
investigate the effect of radiotherapy on patients, we use a number of 
cervical cancer patients in the dataset GSE3578[35] that contains the 
sequencing changes of mRNA expression during therapy. We use NCI-60 
cancer cell lines in a more homogeneous environment as the validation 
datasets: GSE32474[36] and GSE5949[37], which were widely used in 
exploring the underlying mechanisms of cancer and for developing 
drugs[38-40]. As an additional validation of the cancer cell lines, we study 
the integrated datasets: GSE59[41] and GSE7505[32], which record the 
  
abundance of cDNA of the NCI-60 cell lines before and after irradiation, 
respectively. 
Data preprocessing 
For reliable and meaningful statistical analysis, preprocessing of data 
is necessary. Briefly, we first select proper data through ranking and 
variance cutoff. We then apply either linear or logarithmic scales to the 
pertinent index, e.g., the survival time of patients (Table Ⅱ) or the survival 
fraction of cell lines (Table Ⅲ). In the following, we describe the 
preprocessing details for clinical data and cancer cell lines separately. 
Preprocessing of clinical data. For patients, we screen out the cases 
GSE7696, GSE16011 and TCGA-GBM from GEO and TCGA primarily. 
All clinical data are filtered according to the following criteria: (1) null and 
void cases were removed (for example, lost record, abnormal expression, 
and rewritten data), and patients with both mRNA expression and the 
corresponding clinical information were selected; (2) one clinical index 
was used to classify patients (e.g., survival time or subtypes of patients). 
The GSE3578 (cervical cancer patient set) has relatively adequate, 
complete clinical and gene expression information, so it was chosen as an 
additional validation of the ability of RSGGC to evaluate therapy, from 
  
which samples were classified according to the difference in therapeutic 
strategies and checking time. For convenience, samples were classified on 
a logarithmical scale to balance the survival time and the relevant order of 
magnitude of samples. Table Ⅱ shows the physiological or pathological 
brief summary and grouping results. 
Preprocessing of cell lines data. We match the description and 
annotation of the experimental samples with the expression profile, and 
remove samples with missing information. We adopt only the cancer cell 
lines described in previous work[32] and label them with the SF value. The 
radiosensitive and radioresistant lines can be represented by the replication 
rate, cell migration capacity, and SF under specific condition or 
environment. We use the SF value after receiving irradiation of different 
dosage level to characterize cell's radiosensitivity / radioresistance. All the 
cell line datasets are ranked according to the SF values of the cell lines after 
receiving 2Gy, 5Gy, and 8Gy irradiation, denoted by SF2, SF5, and SF8, 
respectively[32]. Table Ⅲ shows the method of sampling groups for 
different radiation dosage, where the low dose irradiation dataset (2Gy) is 
grouped linearly according to SF2, such as deciles or quartiles, while the 
  
high dose irradiation datasets (5Gy and 8Gy) have logarithmical bins 
according to SF5 and SF8. The different ways of data binning were adopted 
just for convenience.  
Correlation matrix and RSGGC measure 
Correlation matrix. A basic fact in systems biology and biomedical 
science is that genes are not isolated with each other but work collectively 
as an interacting network, regardless of whether the underlying process is 
intracellular or extracellular. To characterize the responses of patients or 
cancel cell lines to irradiation, we introduce the measure of RSGGC by 
considering the differences among sample groups and the corresponding 
inherent dynamic relationship from the point of view of a complex network. 
A prerequisite to defining RSGGC is the correlation matrix. To begin, 
for a given dataset, we rank all the genes by the inter-sample variance with 
a proper cutoff to ensure computational efficiency, taking into account the 
balance of heterogeneity of the platforms as in previous work[42]. The 
resulting M×N expression matrix (for M genes and N samples) are ordered 
again by some index, e.g., the survival rate or subtypes. We then divide the 
matrix into different sections: M × 𝑛1, M × 𝑛2, ⋯, where 𝑛1 + 𝑛2 + ⋯ =
N . For each sectional expression matrix, we calculate its Pearson's 
  
correlation matrix from all the gene pairs based on the available samples, 
which leads to an M-dimensional, fully connected, real symmetric matrix, 
with each element characterizing the similarity in the expression level of 
the two genes. To distinguish this M×M matrix from a gene co-expression 
network, we do not set any threshold so as to maintain the original 
correlation between the genes, and obtain an adjacency matrix without 
information loss, with the element of the matrix given by 
ρX,Y =
cov(𝑋, 𝑌)
𝜎𝑋 ∙ 𝜎𝑌
(1) 
where cov(𝑋, 𝑌) stands the covariance between variables X and Y (genes), 
𝜎𝑋  and 𝜎𝑌  are the standard deviations (SD) of the two variables, 
respectively. 
After the data is filtered and grouped, we calculate the intra-sample 
variance of a single gene for one total dataset. Some datasets provide gene's 
expression data, while others record the original expression profiles of 
RNA fragments. For the former, it is straightforward to calculate the 
variance but for the latter, we first merge the multiple probes that match 
the same genes via arithmetic averaging before calculating the variance. 
Probes without the corresponding gene names are dropped from the 
  
calculation. The detailed information of the remaining gene number in each 
step is presented in Table S1. 
To treat the different datasets on an equal footing, it is necessary to 
determine a variance cutoff. In particular, the datasets are obtained from 
different platforms and are processed by probe merging, and each single 
dataset contains a different number of genes. One difficulty is that, after 
ranking by the variance size, many genes have values of variance that are 
close to each other. Moreover, invalid genes in the data lead to wasted 
computation. In addition, certain genes have almost the same expression 
among diverse cells or environment. To overcome these difficulties, we use 
the insights from previous work[43, 44] and choose the first 8000 genes 
with large variance to ensure that they are computationally distinct without 
loss of generality or universality of the results. Since not all 31 radiation 
sensitive genes are included in the top-8000 large variance genes, we 
generate the 31 genes contained in the gene list then complement it with 
the 8000th genes by means of variance. The variance distribution of the 31 
genes is presented in Table S2).  
RSGGC measure. In network science, a large number of centrality 
  
measures have been introduced in different contexts[45]. For example, 
degree centrality (DC) represents the number of edges of a node in the 
network, closeness centrality (CC) characterizes how close a pointed node 
from other nodes[46], betweenness centrality (BC) reflects a node's 
intermediary status of route or pathway in the network[47, 48], and 
eigenvector centrality (EC) measures the relative influence of a node in the 
network[49]. We focus on the EC of the correlation matrix as it is 
appropriate to our task. In general, the eigenvector ?⃗?  associated with the 
maximum eigenvalue of the adjacency matrix is closely related to the 
asymptotic behavior of the collective dynamics on the network and 
control[31]. Let 𝑥𝑖 be the component of the eigenvector corresponding to 
node i. The EC of node i is given by 
𝑥𝑖 =
1
𝜆
∑ 𝑥𝑗
𝑗𝜖𝑁𝑖
=
1
𝜆
∑𝑎𝑖𝑗𝑥𝑗   (2)
𝑗𝜖𝑀
 
where 𝑁𝑖 is the set of node i's neighbors, M is the set of all nodes in the 
network, and 𝑎𝑖𝑗 is the element of the Pearson's correlation matrix A. The 
vector form of Eq. 2 is 
𝐀 ∙ 𝑥 = 𝜆𝑥   (3) 
Our RSGGC measure is defined in terms of EC. In particular, for all the 
  
selected genes, RSGGC is the ratio of the EC of the focal group to that of 
the entire gene set: 
RSGGC =
∑ |𝑥𝑖|𝑛
∑ |𝑥𝑖|𝑁
  (4) 
where n is the number of genes in the radiation sensitivity gene group and 
N=8000 is the total number of genes in the whole set. For the available data 
set in our study, we have n=31 and N=8000. The absolute values in the 
sums indicate a focus on the importance of individual genes rather than 
distinguishing the detailed passive or active role of a specific gene in the 
system. The RSGGC value characterizes the topological and dynamical 
properties of a small group of genes in the whole gene network. 
For a group, the correlation matrix represents its average level under 
various circumstances. The 8000×N matrices, with N being the sample 
size of each entire dataset, are treated as described in Table Ⅱ and Table 
Ⅲ so that the within-group RSGGC values can be computed. The multi-
step analysis is summarized as a workflow chart, as shown in Fig. 2.  
  
Results 
Power of RSGGC as a predictor of radiotherapy outcome for clinical 
patients 
We calculate RSGGC for each classified clinical patient group, as 
shown in Fig. 3. The striking finding is the robust positive correlation 
between the RSGGC value and the survival time, indicating that the 
patients with a higher RSGGC score have longer expected survival time 
after radiotherapy. That is, radiotherapy is more effective for patients with 
a higher RSGGC score. More specifically, the Pearson's correlation 
coefficient for the clinical data in Fig. 3(A-C) are 0.96, 0.83, and 0.87, 
respectively, with the significance index values of 0.06, 0.02, and 0.19 
(Table S3). After random grouping of the clinical data, the positive 
correlation is lost completely (Fig. S1), providing strong evidence for the 
reliability of RSGGC as a quantitative indicator of the effect of 
radiotherapy. The finding of the positive correlation between RSGGC and 
patient survival time is unprecedented and practically significant, as it can 
serve as the base for more reliable prediction of the outcome of 
radiotherapy for cancer patients.  
Ability of RSGGC to predict radiation outcome in cell line 
experiments 
Observation of the survival fraction of cancer cell lines in response to 
  
radiation in experiments is more straightforward and more controllable 
than clinical tests with patients. Our data analysis suggests that the results 
from experimental cell lines at the microscopic level strongly corroborate 
the role of RSGGC in clinical tests. Fig. 4 shows the downtrend 
relationship between the RSGGC value and the survival fraction (SF), 
which is completely consistent with the results from the clinical data. In 
particular, the group of cancer cell lines with higher RSGGC scores has 
lower survival fraction after radiation, corresponding to longer survival 
time of patients. 
The values of Pearson's correlation coefficients of RSGGC and SF in 
Fig. 4 are -0.77 and -0.91, respectively, with the significance index values 
of 0.01 and 0.09 (More statistics are presented in Table S1). Similar results 
of negative correlation between RSGGC and SF have been obtained from 
the two datasets with larger irradiation doses (5Gy and 8Gy, see Fig. S2). 
In clinical practice, the general protocol for radiotherapy consists of daily 
exposure to fractionized radiation of 2Gy irradiation for 5~7 weeks. A 
dosage over 2Gy is in fact harmful to patient's health. Thus, the relationship 
between the survival fraction with 2Gy and RSGGC is practically 
  
significant for generating quantitative patient prognosis. 
Further exploitation of RSGGC for GBM subtypes  
The results in above focus on the relationship between RSGGC and 
the survival time for clinical cases of GBM, where information about the 
detailed subtypes of GBM is ignored. In a previous experimental study[50], 
it was found that the subtypes can have quite different radiation therapy 
effects. For example, radiation can have a significant effect on the subtypes 
“Classical”, “Mesenchymal”, and “Neural”, but the effect is small for the 
subtype “Proneural”. We ask whether RSGGC is capable of characterizing 
the radiation therapy effects at the subtypes level of GBM. To address this 
issue, we group cases according to the subtypes rather than the survival 
time and calculate the RSGGC values. Table Ⅳ presents the detailed 
clinical index and RSGGC for the four subtypes: Classical, Mesenchymal, 
Neural, and Proneural. We see that the first three subtypes have similar 
values of RSGGC, which are larger than that of the fourth subtype 
(Proneural). This coincides well with the therapeutic effect observed from 
the experimental studies of these subtypes. The general result is that 
radiation therapy is more effective for subtypes with a larger value of 
RSGGC.  
  
Mechanism of RSGGC as an estimator and predictor of radiotherapy 
effect 
Our computations and analysis taking into account the survival time 
of clinical patients, the survival fraction of cancer cell lines, or different 
subtypes, give strong evidence that RSGGC is effective for assessing and 
predicting the radiotherapy effect against cancer. A plausible reason for the 
power of RSGGC is that the corresponding selected genes may participate 
in the key pathways associated with repairing DNA damage, activating cell 
cycle checkpoints or maintaining signal transduction pathways after the 
irradiation, either directly or indirectly. To verify this conjecture, we 
employ clinical data[35] from cervical cancer patients prior to and during 
radiotherapy to test how the RSGGC scores calculated from the group of 
genes change as radiotherapy treatment is being implemented. Specifically, 
we classify the expression profile into two groups: prior to or during 
treatment, as shown in Fig. 5. We find that the RSGGC scores of patients 
receiving radiotherapy increase dramatically in comparison with those 
prior to the therapy. We also utilize the time sequences of samples with 
irradiation process obtained from two independent datasets: GSE59 and 
GSE7505, the cDNA microarrays of NCI-60 cell lines before and after 
  
irradiation[32, 41]. Since the datasets are from different experimental 
platforms, we consider only the common genes of the cell lines. After 
classifying the lines as describe in Materials and Methods, we calculate the 
RSGGC values before and after irradiation, as shown in Fig. 5. We find 
that, for the three different irradiation dosages, the RSGGC values of the 
groups with low SF decrease drastically while those with high SF increase, 
indicating that the effects -of irradiation at the molecular level vary for 
different cancer cell lines. The observable response of RSGGC to 
irradiation implies again its potential power in predicting the effect of 
irradiation therapy. In a general sense, RSGGC can effectively be regarded 
as a geometrical indicator of the activity of the radiosensitive gene group 
during irradiation. Since the centrality of the whole set of genes is 
normalized, an increase in the RSGGC score for a subset of genes implies 
that the centrality values of the remaining genes must decrease.  
  
Discussion  
A standard and widely used method to treat cancer patients is 
radiotherapy. An outstanding problem in medical science is to predict the 
survival time of a patient who has undergone radiotherapy. A major 
deficiency of previous work is the focus on gene expression in cells directly 
pertinent to radiosensitivity with factors such as the response of a cancer 
patient to irradiation and the patient survival time totally ignored. To 
overcome the deficiency and to devise a more accurate and reliable 
predictor of the patient survival time, we exploit modern complex network 
science to articulate a geometric approach to estimating and predicting the 
effect of radiotherapy on cancer. In particular, we propose a measure, the 
radiosensitive gene group centrality (RSGGC), that can be used to predict 
the survival time of a patient undergoing radiotherapy. We validate the 
predictive power of RSGGC by using data from both clinical patients and 
experimental cancer cell lines. Results from clinical data reveal a positive 
correlation between RSGGC and the survival time of the patients going 
through radiotherapy. Since, in clinical practice, a patient's prognosis is 
influenced by multiple factors[51, 52] that can introduce fluctuations in the 
outcomes (Table S1), we also systematically analyze data from cancer cell 
  
lines, which are more reliable due to the homogeneous microenvironment 
and the controllability of external conditions in experiments. Results from 
cancer cell lines support our finding from the clinical data in a completely 
consistent way: the cell lines with higher RSGGC values are more sensitive 
to irradiation and thus have smaller values of the survival fraction.  
RSGGC as a novel indicator/predictor for characterizing 
radiosensitivity from a geometric viewpoint has potential advantages over 
the traditional clinical indicators. RSGGC can lead to new insights into 
understanding the relationship among the known radiosensitive gene 
signatures and can be used for data based analysis of extensive risk gene 
sets, intracellular pathways regulation and control.  
  
References 
[1] Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the 
response of cancer and normal tissues to radiation. Nat Rev Drug Disc. 
2013;12:526-42. 
[2] Eschrich S, Zhang H, Zhao H, Boulware D, Lee J-H, Bloom G, et al. 
Systems biology modeling of the radiation sensitivity network: a biomarker 
discovery platform. Inter J Radia Oncol Biol Phys. 2009;75:497-505. 
[3] Zhu C-Q, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. 
Prognostic and predictive gene signature for adjuvant chemotherapy in 
resected non--small-cell lung cancer. J Clin Oncol. 2010;28:4417-24. 
[4] Van De Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil 
DW, et al. A gene-expression signature as a predictor of survival in breast 
cancer. New Engl J Med. 2002;347:1999-2009. 
[5] Lee HJ, Lee J-J, Song IH, Park IA, Kang J, Yu JH, et al. Prognostic and 
predictive value of NanoString-based immune-related gene signatures in a 
neoadjuvant setting of triple-negative breast cancer: relationship to tumor-
infiltrating lymphocytes. Breast Cancer Res Treat. 2015;151:619-27. 
[6] Bing Z, Tian J, Zhang J, Li X, Wang X, Yang K. An Integrative Model 
of miRNA and mRNA Expression Signature for Patients of Breast Invasive 
  
Carcinoma with Radiotherapy Prognosis. Cancer Biothera Radiopharma. 
2016;31:253-60. 
[7] Kim HS, Kim SC, Kim SJ, Park CH, Jeung H-C, Kim YB, et al. 
Identification of a radiosensitivity signature using integrative metaanalysis 
of published microarray data for NCI-60 cancer cells. BMC Geno. 2012;13 
1  
[8] Palla G, Der\'e nI, Farkas Ies, Vicsek Tas. Uncovering the overlapping 
community structure of complex networks in nature and society. Nature. 
2005;435:814-8. 
[9] Barthe lM. Spatial networks. Phys Rep. 2011;499:1-101. 
[10] Holme P, Saram\"a kJ. Temporal networks. Phys Rep. 2012;519:97-
125. 
[11] Wang W-X, Lai Y-C, Grebogi C. Data based identification and 
prediction of nonlinear and complex dynamical systems. Phys Rep. 
2016;644:1-76. 
[12] Kauffman S, Peterson C, Samuelsson Bor, Troein C. Random Boolean 
network models and the yeast transcriptional network. Proc Nat Acad Sci 
(USA). 2003;100 14796-9  
  
[13] Barabasi A-L, Oltvai ZN. Network biology: understanding the cell's 
functional organization. Nat Rev Genet. 2004;5:101-13. 
[14] Pastor-Satorras R, Vespignani A. Epidemic spreading in scale-free 
networks. Phys Rev Lett. 2001;86:3200. 
[15] Brockmann D, Helbing D. The hidden geometry of complex, network-
driven contagion phenomena. Science. 2013;342:1337-42. 
[16] Proulx SR, Promislow DEL, Phillips PC. Network thinking in ecology 
and evolution. Trends Ecol Evolu. 2005;20 345-53  
[17] Alon U. Network motifs: theory and experimental approaches. Nat 
Rev Genet. 2007;8 %6:450-61. 
[18] Jiang J, Huang Z-G, Seager TP, Lin W, Grebogi C, Hastings A, et al. 
Predicting tipping points in mutualistic networks through dimension 
reduction. Proc Natl Acad Sci (USA). 2018:201714958. 
[19] Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets 
systems biology. Nat Rev Cancer. 2012;12:553-63. 
[20] Pujana MA, Han J-DJ, Starita LM, Stevens KN, Tewari M, Ahn JS, et 
al. Network modeling links breast cancer susceptibility and centrosome 
dysfunction. Nat Genet. 2007;39:1338-49. 
  
[21] Chuang H-Y, Lee E, Liu Y-T, Lee D, Ideker T. Network-based 
classification of breast cancer metastasis. Mole Sys Biol. 2007;3:140. 
[22] Gevaert O, De Smet F, Timmerman D, Moreau Y, De Moor B. 
Predicting the prognosis of breast cancer by integrating clinical and 
microarray data with Bayesian networks. Bioinfo. 2006;22:e184-e90. 
[23] Ivliev AE, Ac't Hoen P, Sergeeva MG. Coexpression network analysis 
identifies transcriptional modules related to proastrocytic differentiation 
and sprouty signaling in glioma. Cancer Res. 2010;70:10060-70. 
[24] Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 
2004;4:540-50. 
[25] Altieri DC. Survivin, cancer networks and pathway-directed drug 
discovery. Nat Rev Cancer. 2008;8:61-70  
[26] Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et 
al. The sequence of the human genome. Science. 2001;291:1304-51. 
[27] Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network 
for global discovery of conserved genetic modules. Science. 
2003;302:249-55. 
[28] Freeman LC. Centrality in social networks conceptual clarification. 
  
Soc Net. 1978;1:215-39. 
[29] Gomez D, Gonz\'a l-AueE, Manuel C, Owen G, del Pozo M, Tejada J. 
Centrality and power in social networks: a game theoretic approach. Math 
Soc Sci. 2003;46:27-54. 
[30] Borgatti SP, Everett MG. A graph-theoretic perspective on centrality. 
Soc Net. 2006;28:466-84. 
[31] Aguirre J, Papo D, Buld\'u JM. Successful strategies for competing 
networks. Nat Phys. 2013;9:230-4. 
[32] Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, 
et al. Integrating global gene expression and radiation survival parameters 
across the 60 cell lines of the National Cancer Institute Anticancer Drug 
Screen. Cancer Res. 2008;68:415-24. 
[33] Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou M-F, 
et al. Stem cell--related "self-renewal" signature and high epidermal 
growth factor receptor expression associated with resistance to 
concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 
2008;26:3015-24. 
[34] Gravendeel LAM, Kouwenhoven MCM, Gevaert O, de Rooi JJ, 
  
Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas 
are a better predictor of survival than histology. Cancer Res. 2009;69:9065-
72  
[35] Iwakawa M, Ohno T, Imadome K, Nakawatari M, Ishikawa K-i, Sakai 
M, et al. The radiation-induced cell-death signaling pathway is activated 
by concurrent use of cisplatin in sequential biopsy specimens from patients 
with cervical cancer. Cancer Biol Thera. 2007;6:905-11. 
[36] Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, 
et al. Topoisomerase I levels in the NCI-60 cancer cell line panel 
determined by validated ELISA and microarray analysis and correlation 
with indenoisoquinoline sensitivity. Mole Cancer Therap. 2009;8:1878-84. 
[37] Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, 
Ziegler MS, et al. Multifactorial regulation of E-cadherin expression: an 
integrative study. Mole Cancer Thrap. 2010:1535-7163. 
[38] Shoemaker RH. The NCI60 human tumour cell line anticancer drug 
screen. Nat Rev Cancer. 2006;6:813-23. 
[39] Gao H, Korn JM, Ferretti Sep, Monahan JE, Wang Y, Singh M, et al. 
High-throughput screening using patient-derived tumor xenografts to 
  
predict clinical trial drug response. Nat Med. 2015;21:1318-25. 
[40] Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, 
Karpovich J, et al. A strategy for predicting the chemosensitivity of human 
cancers and its application to drug discovery. Proc Nat Acad Sci (USA). 
2007;104:13086-91. 
[41] Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. 
Systematic variation in gene expression patterns in human cancer cell lines. 
Nat Genet. 2000;24:227-35. 
[42] Volinia S, Croce CM. Prognostic microRNA/mRNA signature from 
the integrated analysis of patients with invasive breast cancer. Proc Nat 
Acad Sci (USA). 2013;110:7413-7. 
[43] Oldham MC, Horvath S, Geschwind DH. Conservation and evolution 
of gene coexpression networks in human and chimpanzee brains. Proc, Nat 
Acad Sci (USA). 2006;103 17973-8  
[44] Zhang B, Horvath S. A general framework for weighted gene co-
expression network analysis. Stat Appl Gene Mole Biol. 2004;4:Article17. 
[45] Newman MEJ. Networks: An Introduction: Oxford University Press; 
2010. 
  
[46] Bavelas A. Communication patterns in task-oriented groups. J Acou 
Soc Ame. 1950;22:725-30. 
[47] Freeman LC. A set of measures of centrality based on betweenness. 
Sociometry. 1977:35-41. 
[48] Park KH, Lai YC, Ye N. Characterization of weighted complex 
networks. Phys Rev E. 2004;70:026109. 
[49] Bonacich P. Power and centrality: A family of measures. Ame J Socio. 
1987;92:1170-82. 
[50] Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, 
et al. Integrated genomic analysis identifies clinically relevant subtypes of 
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, 
and NF1. Cancer Cell. 2010;17:98-110. 
[51] Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. 
Patterns of gene expression that characterize long-term survival in 
advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11:3686. 
[52] Wang MJ, Ping J, Li Y, Adell G, Arbman G, Nodin B, et al. The 
prognostic factors and multiple biomarkers in young patients with 
colorectal cancer. Sci Rep. 2015;5:10645. 
  
  
  
Figures & Figure Legends 
 
Figure 1. Schematic illustration of the effects of radiation sensitive 
genes on the intercellular interaction or correlation of genes in cells: 
(A) before and (B) after irradiation. The red and orange blocks represent 
the radiation sensitive and the remaining genes, respectively. For simplicity 
  
and clarity, only a small fraction of the genes are demonstrated. The links 
in the network are drawn according to the open database STRING-DB. The 
thickness of a line between a pair of genes indicates the interaction strength 
between the genes. A comparison between (A) and (B) gives a glimpse of 
one possible change in the interaction strength due to irradiation. 
  
  
 
Figure 2. Workflow of multi-step calculation of RSGGC. 
  
  
 
Figure 3. Correlation between RSGGC score and survival time of 
GBM patients. Datasets are (A) GSE7696, (B) GSE16011, and (C) 
TCGA-GBM. The horizontal axis denotes the mean survival time for each 
sample group (black squares). A semi-logarithmic scale is used. The 
positive correlation between patients’ RSGGC value and the mean survival 
time has been identified in all the datasets. The dip in the RSGGC score in 
the region of small survival time in (C) is due to the unusually short-living 
samples in the dataset. 
  
  
 
Figure 4. Negative correlation between RSGGC and survival fraction 
of cancer cell lines. The datasets are (A) GSE32474 and (B) GSE5949 
with 2Gy radiation. The horizontal axis is the mean SF value of the samples 
within the group. RSGGC exhibits a negative relationship with the survival 
fraction, which is completely consistent with the results in Fig. 3. 
  
  
 
Figure 5. Applicability of RSGGC to cervical cancer patients and cell 
lines. (A) RSGGC values of cervical cancer patients prior to or during 
irradiation treatment. There is a dramatic increase in the RSGGC value as 
a result of the irradiation treatment. (B-D) RSGGC values of NCI-60 
cancer cell lines before and after irradiation, with dosages of 2, 5, and 8Gy, 
respectively. The solid and open squares represent the RSGGC values of 
each group of cell lines before (from data in GSE59) and after receiving 
the irradiation (from data in GSE7505). 
  
  
Tables in Manuscript 
TableⅠ. Datasets used in this article.  
Dataset Brief Description Platform[1] 
GSE59 cDNA microarrays of NCI-60 cancer cell lines GPL167, 169 
GSE3578 mRNA expression of cervical cancer patients during therapy GPL2895 
GSE5949 mRNA expression of NCI-60 cancer cell lines GPL91~95 
GSE7505 cDNA microarrays of NCI-60 cancer cell lines after radiation GPL5080 
GSE7696 mRNA expression of GBM patients GPL570 
GSE16011 mRNA expression of GBM patients GPL8542 
GSE32474 mRNA expression of NCI-60 cancer cell lines GPL570 
TCGA-GBM GBM patient samples from TCGA GPL570 
[1] We adopt GEO accession for data sets to simplify the description of the GEO Platform (GPL). The detailed information, which can be found 
from the website of National Center for Biotechnology Information (NCBI), is:  
(1) GPL91~95, Affymetrix Human Genome U95A U95E Array; 
(2) GPL167, 169, 10kPrint3, 10kPrint2 of spotted DNA/cDNA (non-commercial); 
(3) GPL570, Affymetrix Human Genome U133 Plus 2.0 Array; 
(4) GPL2895, GE Healthcare/Amersham Biosciences CodeLink Human Whole Genome Bioarray; 
(5) GPL5080, NHGRI Homo sapiens 6K of spotted DNA/cDNA; 
(6) GPL8542, Affymetrix GeneChip Human Genome U133 Plus 2.0 Array.   
  
Table Ⅱ. Clinical Information and Groups of Patients in Different Datasets 
Dataset 
Sample 
Size 
Grouping to the Survival Time (K days) 
Mean Survival Time  
(K days)[1] 
Mean Age Gender (M/F) 
GSE7696 65 0~0.25~0.50~∞ 0.438 51.178 48/17 
GSE16011 180 
0~0.1~0.2~0.4~ 
0.8~1.6~3.2~∞ 
0.836 49.986 122/58 
TCGA-GBM 318 
0~0.25~0.50~ 
1.00~2.50~∞ 
0.563 56.138 195/123 
[1]  Only the patients with a clinical event (death) are taken into account. 
 
  
  
Table Ⅲ. Method to group cancer cell lines based on the survival fractions under different radiation dosages (2, 5, and 
8Gy, respectively). 
Dataset Sample Size 
Grouping to the Survival Fraction 
SF2 SF5 SF8 
GSE59 60 quartiles 
0~0.01~0.05~ 
0.10~0.25~1.00 
0~0.001~0.005~ 
0.010~0.25~1.00 
GSE5949 60 quartiles 
GSE7505 60 quartiles 
GSE32474 174 deciles 
0~0.005~0.05~ 
0.1~0.25~1.00 
0~0.0005~0.005~0.010~ 
0.025~0.05~0.1~1.0 
 
  
  
Table Ⅳ. Characteristic description of clinical subtypes of GBM and the corresponding RSGGC values. 
Subtypes Sample Size[1] Age (mean) 
Gender  
(M/F) 
Therapeutic 
Effect[2] 
HR[2] P-value[2] RSGGC(%) 
Classical 141 10.9~86.59 (58.9) 83/58 significant 0.45 0.02 0.321 
Mesenchymal 151 24.4~84.8 (59.6) 91/60 significant 0.54 0.02 0.357 
Neural 82 23.1~88.6 (59.9) 54/28 effective 0.56 0.1 0.334 
Proneural 129 17.7~89.3 (53.9) 77/52 less effective 0.80 0.4 0.223 
[1] The total sample size is 503, which includes patients with clinical events (death). 
[2] The therapeutic effect, the values of hazard ratio (HR), and P-values are from Ref. [50]. 
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1. Genes filtrating & probes merging 
 
As mentioned in the main text, the datasets used in this work were obtained from various 
platforms (Table-1 in the main text). Table-S1 describes the detailed filtrating or merging 
process for datasets.  
 
Table-S1 Data Filtrating and Merging Processes 
Dataset Platform[1] Types 
Genes or 
Fragments 
Original 
Rows 
Removing 
NULL or 
invalid* 
Merging 
Multiple 
Probes 
Utilizing in 
Paper 
RS genes   
Included 
GSE59 GPL167, 169 cDNA fragments 9984[2] 7208 6182 1445[3] 6 
GSE3578 GPL2895 mRNA fragments 54676 24467 19578 8000 30 
GSE5949 GPL91~95 mRNA fragments 63178[4] 42499 19962 8000 31 
GSE7505 GPL5080 cDNA fragments 6728 6126 5743 1445[3] 6 
GSE7696 GPL570 mRNA fragments 54675 45782 23519 8000 31 
GSE16011 GPL8542 mRNA genes 17527 17454 17454 8000 29 
GSE32474 GPL570 mRNA fragments 54675 45782 23519 8000 31 
TCGA-GBM GPL570 mRNA genes 12402 12402 12402 8000 31 
[1] We use the GEO accession as in the main text. 
[2] Only GPL167 is described. 
[3] There 1445 remaining genes outside of the intersection between GSE59 and GSE7505 (See also Table-S2). 
[4] This row shows the integrating results of the five platforms GPL91~GPL95, and the number of genes for each 
platform is 12626 (12182), 12621 (9118), 12647 (7541), 12645 (5535), and 12639 (8123). 
 
  
  
2. Program Realization 
 
We carried out data filtrating using software R (version 3.1.3 in this paper), MS Excel 2013 and 
MATLAB2014a (v8.3.0.532). The R program was applied to initial screening of the valid 
genes / fragments or to matching the expression with clinical data / survival fraction / surviving 
time / subtypes information. In addition, we merge the RNA fragments by R order DATA2<-
aggregate.data.frame(DATA1,by=list (DATA$genes), FUN=mean), where 
DATA1 is the original mRNA fragments data, DATA2 is the outcome of merging, and all data 
processed by arithmetic average according to gene names DATA$genes. The variance can be 
obtained by using R or Excel with the executive order being the answer<-
apply(DATA,1,var), or function VAR.P( ), respectively. Considering that MATLAB is 
specialized in matrix computation, we deal with grouped data through the function corr( ) 
to get the correlation matrix and to obtain the maximum eigenvector by order 
[v,~]=eig(matrix). It is noteworthy that not all 31 radiation sensitive genes are in the 
top 8000 (see Table-S2). 
 
  
  
Table-S2 Distribution of the variance of 31 RS genes from the corresponding datasets 
31 Genes GSE59[1] GSE3578 GSE5949[2] GSE7505 GSE7696 GSE16011 GSE32474 TCGA-GBM 
ACTN1 1167/392 2469 2992 2501 1922 868 4723 1016 
ANXA2 1101/— 138 8865 —— 1587 614 2348 964 
ANXA5 1324/— 3845 8571 5569 1862 2273 3124 2929 
ARHGDIB 94/— 686 47 2141 4921 2494 733 1653 
CAPNS1 4074/— 2779 17411 5223 4168 5160 7397 6294 
CBR1 853/— 815 2086 2186 2488 239 803 1165 
CCND1 —— —— 1143 3763 1233 1069 458 796 
CD63 2871/— 616 6433 —— 2639 4193 3702 7035 
CORO1A 2131/— 4775 117 4294 2713 2240 605 1363 
CXCR4 —— 2904 338 —— 898 707 280 778 
DAG1 1292/790 1920 8227 5544 11032 6025 3964 5565 
EMP2 1161/— 1271 4029 4696 2406 1623 1497 568 
HCLS1 874/— 8057 2933 1347 1069 574 263 669 
HTRA1 326/240 332 268 —— 1968 3075 196 861 
ITGB5 596/— 15919 1207 5355 5210 1282 3309 3316 
LAPTM5 543/61 587 569 3564 1332 992 374 824 
LRMP 139/302 6361 4811 2045 8883 3072 2043 5590 
MYB 4923/— 1886 2366 2936 16495 3944 742 3264 
PFN2 609/— 10789 271 4365 2061 4161 322 1507 
PIR —— 8636 406 5083 724 495 354 500 
PKM2[2] 3995/— 137* 14907* —— 4029* 3424 6799* 2708 
PTMS 3334/— 3855 6979 5065 13411 1717 13837 8874 
PTPRC 44/11 8529 5900 2706 5007 1571 1507 968 
PTPRCAP 4847/— 17377 749 2630 13145 13894 2335 8606 
PYGB 1385/— 5217 10898 4949 12048 5042 9241 2343 
RAB13 —— 546 1737 —— 5070 —— 970 3607 
RALB 2531/— 7154 12357 4412 9849 7619 5060 4883 
SCRN1 456/3 16020 764 —— 2641 3386 329 1230 
SQSTM1 2839/1293 675 13261 —— 10817 —— 8074 3537 
TWF1 —— 10019 18719 1812 20938 10608 10242 5007 
WAS 1014/272 3887 4125 2215 17564 14531 14110 9423 
Total 26/10 30 31 23 31 29 31 31 
[1] Two columns represent the variance distribution of two GPL167, GPL169 respectively. 
[2] GPL91~GPL95 utilized in GSE5949 are analyzed integrally here. 
[3] Line symbol means the platforms doesn’t contain the gene; the star symbol means some datasets we choose 
PKM as the RS gene instead of PKM2. 
  
  
3. Biostatistics information 
 
Table-S3 lists the detailed information about the biostatistics of the results in the main text.  
 
Table-S3 Biostatistics information of the results in the main text 
Dataset 
Pearson’s 
Coef 
R2 P-value 
Group 
Num. 
GSE32474(SF2)[1] -0.76993 0.54189 0.00919 10 
GSE5949(SF2)[1] -0.91284 0.7499 0.08716[2] 4 
TCGA-GBM 0.87008 0.67606 0.0551 5 
GSE16011 0.83134 0.62935 0.02044 7 
GSE7696 0.9569 0.83133 0.18758[2] 3 
[1] Included is only the 2Gy dose case. 
[2] The P-values of GSE5949 and GSE7696 are large because of the small amount of grouping of the two datasets. 
The absolute values of Pearson’s correlation coefficient of the two curves are close to one, implying underlying 
regularity. 
 
  
  
4. Random grouping of three clinical datasets 
 
We divide samples into random groups regardless of patient’s survival time and calculate the 
corresponding RSGGC values. The black solid lines in Fig. S1 correspond to the results from 
the whole sample set without grouping. For the randomized cases, there is no indication of any 
correlation between the RSGGS value and the patients’ survival time demonstrated in the 
main text. 
 
Figure-S1 RSGGC values of random grouping of clinical datasets. 
  
  
5. RSGGC of cancer cell lines in high irradiation dose  
 
The results from cancer cell lines under relatively high irradiation doses (5 Gy and 8 Gy) are 
shown in Fig-S2 (the corresponding results for the case of 2 Gy can be found in Fig. 4 in the 
main text).  
 
Figure-S2 RSGGC values of cancer cell lines subject to higher irradiation 
dose. The top and bottom rows show the results from GSE32474 and GSE5949, 
respectively. The left and right columns are results for irradiation doses of 5Gy 
and 8Gy, respectively.  
 
